Anrikefon (HSK21542): Efficacy and Safety for Postoperative Pain

A 2026 systematic review and meta-analysis synthesizes evidence from three randomized controlled trials (n=718) conducted up to November 2025. The analysis evaluates the efficacy and safety of intravenous Anrikefon versus placebo for postoperative pain management. Findings indicate significant improvements in pain scores and reduced rescue analgesic use, with a low reported incidence of adverse events.

Use Cases

• Meta-analysis of pain score improvement (SPID0–24h) based on pooled results from three RCTs.
• Comparative safety assessment based on reported Treatment-Emergent Adverse Events (TEAEs) and postoperative nausea and vomiting (PONV) rates.
• Evaluating rescue analgesic use reduction based on risk ratio calculations within 12 hours post-surgery.
• Assessing patient-reported outcomes based on the proportion achieving a Numerical Rating Scale (NRS) ≤ 3 at 12 hours.

Strengths

• Structured synthesis of evidence from three randomized controlled trials involving 718 patients.
• Analysis employs random-effects models and reports specific statistical measures (e.g., MD=-14.73, RR=0.59) with confidence intervals.
• Openly licensed (CC-BY-4.0) for reuse and sharing.

Limitations

• Underlying trial data and column/variable definitions are not provided, limiting reproducibility of the meta-analysis.
• The dataset's primary content is the review manuscript (DOCX format), not the raw clinical trial data.
• Evidence is based on a limited number of trials (n=3), as noted in the source description.

Provenance

Source

Muhammad Tayyab Azam

Collection Method

Systematic review and meta-analysis of literature from PubMed, Embase, Cochrane CENTRAL, and ClinicalTrials.gov.

Time Range

Trials identified through November 2025.

Freshness

Last updated 2026-03-20.